Anavex Life Sciences Corp (AVXL)

[frrol]

This is not an analysis on ADCS-ADL:

"Next slide ADCS-ADL
This slide is analyzed the same way as the first ADAS-Cog.
The treatment group was 167% more likely to improve when compared to the placebo group with this test. This is very significant, and they also have a good p value of 0.0255."

It's just what the ADCS-ADL slide says.

His analysis of ADAS-Cog is putting in some sample numbers to replicate the mean and p-val. He's showing that we used a one-tail test, and saying this is not a problem. But that's a judgement call (and probably the right one).